News | Myriad Genetics

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Dec 10, 2024 | Financial

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Dec 10, 2024 | Products | Corporate

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Dec 10, 2024 | Products

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

Dec 09, 2024 | Products

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Dec 09, 2024 | Products

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Nov 20, 2024 | Products

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Nov 19, 2024 | Products

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Nov 13, 2024 | Products

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Nov 07, 2024 | Products | Financial | Corporate

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Nov 04, 2024 | Products

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Oct 30, 2024 | Financial

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Oct 16, 2024 | Products

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Oct 15, 2024 | Products

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Oct 08, 2024 | Products

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Oct 03, 2024 | Products

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Oct 01, 2024 | Products | Corporate

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Sep 18, 2024 | Products

Myriad Genetics to Host Investor Event on October 9, 2024

Sep 05, 2024 | Corporate

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Aug 21, 2024 | Corporate

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Aug 06, 2024 | Financial | Corporate

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

Aug 01, 2024 | Products | Corporate

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

Jul 31, 2024 | Corporate

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

Jul 30, 2024 | Financial | Corporate

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

Jul 17, 2024 | Products

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Jul 11, 2024 | Products

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Jul 09, 2024 | Products

Myriad Genetics Earns 2024 Great Place To Work® Certification™

Jul 02, 2024 | Corporate

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

Jun 24, 2024 | Products

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

Jun 11, 2024 | Products

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

Jun 04, 2024 | Products

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

Jun 03, 2024 | Products

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

May 30, 2024 | Products

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

May 23, 2024 | Products

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

May 16, 2024 | Products

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

May 07, 2024 | Corporate | Financial

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

May 07, 2024 | Products | Corporate

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 30, 2024 | Corporate | Financial

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Apr 17, 2024 | Products

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Apr 16, 2024 | Products

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Apr 09, 2024 | Products

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Mar 21, 2024 | Products

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Mar 20, 2024 | Products

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Feb 27, 2024 | Financial | Corporate

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Feb 27, 2024 | Products

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 21, 2024 | Financial | Corporate

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Feb 15, 2024 | Corporate | Products

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Feb 01, 2024 | Corporate

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Jan 30, 2024 | Corporate

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Jan 18, 2024 | Corporate | Products

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Myriad Genetics to Host Investor Event on October 9, 2024

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad Genetics Earns 2024 Great Place To Work® Certification™

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference